Phospholipase D from Streptomyces sp. (PLD)

Phospholipase D (PLD) from Streptomyces species is a well-characterized extracellular enzyme belonging to the HKD superfamily, named after its conserved His-Lys-Asp catalytic motifs. Its primary biological function is the hydrolysis of phosphatidylcholine into phosphatidic acid (PA) and choline, a process central to lipid metabolism and signal transduction. A unique and industrially significant feature of this enzyme is its high transphosphatidylation activity, which allows for the exchange of the phospholipid head group with various alcohols. This capability makes it a vital tool in the biotechnology and pharmaceutical industries for the production of specialized phospholipids like phosphatidylserine. While Streptomyces PLD itself is not a direct therapeutic target for human disease, it serves as a critical structural and functional model for human PLD isoforms (PLD1 and PLD2), which are implicated in cancer, neurodegeneration, and inflammation. Research often utilizes the Streptomyces enzyme to screen for small-molecule inhibitors or to study the fundamental mechanisms of lipid-mediated signaling. In a clinical context, related phospholipases from pathogenic bacteria act as virulence factors by disrupting host cell membranes, though Streptomyces species are generally non-pathogenic soil bacteria. Consequently, the enzyme is primarily viewed as a high-value biocatalyst and a reference protein for drug discovery efforts targeting lipid signaling pathways.

Other names

Phosphatidylcholine phosphatidohydrolaseLipophosphodiesterase IILecithinase DCholine phosphodiesterase

Phospholipase D catalyzes the hydrolysis of the phosphodiester bond in phospholipids, such as phosphatidylcholine, to release phosphatidic acid and a free head group like choline. In the presence of primary alcohols, it preferentially performs a transphosphatidylation reaction, exchanging the head group for the alcohol to form phosphatidylalcohols. While not a primary human therapeutic target, it is used as a model enzyme to study phospholipase inhibitors and as a biocatalyst for synthesizing pharmaceutical-grade phospholipids.